David Colleran - Mar 4, 2023 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role: EVP, General Counsel, Corp Sec
Signature: /s/ David Colleran
Stock symbol: ANIK
Transactions as of: Mar 4, 2023
Transactions value $: -$23,187
Form type: 4
Date filed: 3/7/2023, 03:34 PM
Previous filing: May 12, 2022
Next filing: Mar 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANIK	Common Stock	Options Exercise	$0	+2.5K	+23.79%	$0.00	13K	Mar 4, 2023	Direct	F1, F2
transaction	ANIK	Common Stock	Tax liability	-$23.2K	-734	-5.64%	$31.59	12.3K	Mar 4, 2023	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANIK	Restricted Stock Unit	Options Exercise	$0	-2.5K	-100%	$0.00^*	0	Mar 4, 2023	Common Stock	2.5K	$0.00	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 4, 2020.
F2	Includes 640 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 13, 2022.
F3	Reflects an aggregate of 734 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 4, 2023.
F4	Reflects the closing price of ANIK common stock on March 3, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
F5	Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vested in three equal annual installments beginning March 4, 2021.